To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
133 Current news of Bayerrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Establishment of BlueRock site in Berlin expands company’s footprint and strengthens Bayer’s cell therapy capabilities
Bayer AG announced that BlueRock Therapeutics LP (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. This move comes as part of the company’s focused growth ...
Outlook for 2022 confirmed – confident about the full year despite uncertainty due to global crises
The Bayer Group had a very successful start to 2022. “We achieved outstanding sales and earnings growth, with particularly substantial gains for our agriculture business,” said Werner Baumann, Chairman of the Board of Management, on Tuesday as he presented the quarterly statement for the first ...
Affini-T Therapeutics completes $175 million financing co-led by Vida Ventures and Leaps by Bayer
Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the completion of an oversubscribed $175 million financing co-led by Vida Ventures and Leaps by Bayer, the impact investment unit of Bayer. Additional investors ...
Group sales increase by 8.9 percent (Fx & portfolio adj.) to 44.081 billion euros
The Bayer Group had a successful year in 2021, both operationally and strategically. “We posted substantial growth, strengthened our innovation pipeline and made progress toward our sustainability targets. All this shows that Bayer is on the right track!” said Werner Baumann, Chairman of the ...
Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing
Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG – Leaps by Bayer – 8VC, and Humboldt Fund. New investors in the round include Felicis Ventures and others, joining ...
Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ ...
Group sales rise by 14.3 percent (Fx & portfolio adj.) to 9.781 billion euros
The Bayer Group registered a significant increase in sales and earnings in the third quarter of 2021. “We delivered strong operational performance, with all divisions showing strong growth momentum,” said Werner Baumann, Chairman of the Board of Management, on Tuesday when presenting the ...
Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures
Leaps by Bayer, the impact investment arm of Bayer AG, announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes, with Cavallo Ventures. Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside ...
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform
Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion’s platform is able to produce a variety ...
Net income advances by 40.3 percent to 2.089 billion euros
The Bayer Group had a successful start to 2021. “We’re seeing a good operational performance overall, but we were impacted by negative currency effects as expected,” said CEO Werner Baumann when the quarterly statement for the first quarter of 2021 was published on Wednesday. “Our Crop Science ...